Skip to main content

Oppenheimer Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Tipranks - Tipranks - Fri Jan 9, 4:00AM CST

Oppenheimer analyst Kostas Biliouris maintained a Buy rating on Alnylam Pharma yesterday and set a price target of $500.00. The company’s shares closed yesterday at $422.50.

Claim 70% Off TipRanks Premium

According to TipRanks, Biliouris is a 2-star analyst with an average return of 0.2% and a 41.18% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sarepta Therapeutics, and Legend Biotech.

Currently, the analyst consensus on Alnylam Pharma is a Strong Buy with an average price target of $498.42, a 17.97% upside from current levels. In a report released on January 5, Bernstein also maintained a Buy rating on the stock with a $491.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Alnylam Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.25 billion and a net profit of $251.08 million. In comparison, last year the company earned a revenue of $500.92 million and had a GAAP net loss of $111.57 million

Read More on ALNY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).